Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process
Identifieur interne : 001008 ( Main/Exploration ); précédent : 001007; suivant : 001009Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process
Auteurs : Barry Buckland [États-Unis, Royaume-Uni] ; Robert Boulanger [États-Unis] ; Mireli Fino [États-Unis] ; Indresh Srivastava [États-Unis] ; Kathy Holtz [États-Unis] ; Nikolai Khramtsov [États-Unis] ; Clifton Mcpherson [États-Unis] ; Jamal Meghrous [États-Unis] ; Paul Kubera [États-Unis] ; Manon M. J. Cox [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
Multiple different hemagglutinin (HA) protein antigens have been reproducibly manufactured at the 650 L scale by Protein Sciences Corporation (PSC) based on an insect cell culture with baculovirus infection. Significantly, these HA protein antigens were produced by the same Universal Manufacturing process as described in the biological license application (BLA) for the first recombinant influenza vaccine approved by the FDA (Flublok®). The technology is uniquely designed so that a change in vaccine composition can be readily accommodated from one HA protein antigen to another one. Here we present a vaccine candidate to combat the recently emerged H7N9 virus as an example starting with the genetic sequence for the required HA, creation of the baculovirus and ending with purified protein antigen (or vaccine component) at the 10 L scale accomplished within 38 days under GMP conditions. The same process performance is being achieved at the 2L, 10L, 100 L, 650 L and 2500 L scale. An illustration is given of how the technology was transferred from the benchmark 650 L scale facility to a retrofitted microbial facility at the 2500 L scale within 100 days which includes the time for facility engineering changes. The successful development, technology transfer and scale-up of the Flublok® process has major implications for being ready to make vaccine rapidly on a worldwide scale as a defense against pandemic influenza. The technology described does not have the same vulnerability to mutations in the egg adapted strain, and resulting loss in vaccine efficacy, faced by egg based manufacture.
Affiliations:
- Royaume-Uni, États-Unis
- Angleterre, Connecticut, Grand Londres, Pennsylvanie
- Londres
- University College de Londres
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000030
- to stream PascalFrancis, to step Curation: 001D89
- to stream PascalFrancis, to step Checkpoint: 000014
- to stream Main, to step Merge: 001015
- to stream Main, to step Curation: 001008
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process</title><author><name sortKey="Buckland, Barry" sort="Buckland, Barry" uniqKey="Buckland B" first="Barry" last="Buckland">Barry Buckland</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Biochemical Engineering, University College London, Torrington Place</s1><s2>London WC1E 7JE</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>London WC1E 7JE</wicri:noRegion><orgName type="university">University College de Londres</orgName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Boulanger, Robert" sort="Boulanger, Robert" uniqKey="Boulanger R" first="Robert" last="Boulanger">Robert Boulanger</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Fino, Mireli" sort="Fino, Mireli" uniqKey="Fino M" first="Mireli" last="Fino">Mireli Fino</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Srivastava, Indresh" sort="Srivastava, Indresh" uniqKey="Srivastava I" first="Indresh" last="Srivastava">Indresh Srivastava</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Holtz, Kathy" sort="Holtz, Kathy" uniqKey="Holtz K" first="Kathy" last="Holtz">Kathy Holtz</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Khramtsov, Nikolai" sort="Khramtsov, Nikolai" uniqKey="Khramtsov N" first="Nikolai" last="Khramtsov">Nikolai Khramtsov</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Meghrous, Jamal" sort="Meghrous, Jamal" uniqKey="Meghrous J" first="Jamal" last="Meghrous">Jamal Meghrous</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Kubera, Paul" sort="Kubera, Paul" uniqKey="Kubera P" first="Paul" last="Kubera">Paul Kubera</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>ABEC Corporation</s1><s2>Bethlehem, PA</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Cox, Manon M J" sort="Cox, Manon M J" uniqKey="Cox M" first="Manon M. J." last="Cox">Manon M. J. Cox</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0246271</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0246271 INIST</idno><idno type="RBID">Pascal:14-0246271</idno><idno type="wicri:Area/PascalFrancis/Corpus">000030</idno><idno type="wicri:Area/PascalFrancis/Curation">001D89</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000014</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000014</idno><idno type="wicri:doubleKey">0264-410X:2014:Buckland B:technology:transfer:and</idno><idno type="wicri:Area/Main/Merge">001015</idno><idno type="wicri:Area/Main/Curation">001008</idno><idno type="wicri:Area/Main/Exploration">001008</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process</title><author><name sortKey="Buckland, Barry" sort="Buckland, Barry" uniqKey="Buckland B" first="Barry" last="Buckland">Barry Buckland</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Biochemical Engineering, University College London, Torrington Place</s1><s2>London WC1E 7JE</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>London WC1E 7JE</wicri:noRegion><orgName type="university">University College de Londres</orgName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Boulanger, Robert" sort="Boulanger, Robert" uniqKey="Boulanger R" first="Robert" last="Boulanger">Robert Boulanger</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Fino, Mireli" sort="Fino, Mireli" uniqKey="Fino M" first="Mireli" last="Fino">Mireli Fino</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Srivastava, Indresh" sort="Srivastava, Indresh" uniqKey="Srivastava I" first="Indresh" last="Srivastava">Indresh Srivastava</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Holtz, Kathy" sort="Holtz, Kathy" uniqKey="Holtz K" first="Kathy" last="Holtz">Kathy Holtz</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Khramtsov, Nikolai" sort="Khramtsov, Nikolai" uniqKey="Khramtsov N" first="Nikolai" last="Khramtsov">Nikolai Khramtsov</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Meghrous, Jamal" sort="Meghrous, Jamal" uniqKey="Meghrous J" first="Jamal" last="Meghrous">Jamal Meghrous</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Kubera, Paul" sort="Kubera, Paul" uniqKey="Kubera P" first="Paul" last="Kubera">Paul Kubera</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>ABEC Corporation</s1><s2>Bethlehem, PA</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Cox, Manon M J" sort="Cox, Manon M J" uniqKey="Cox M" first="Manon M. J." last="Cox">Manon M. J. Cox</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Protein Sciences Corporation, 1000 Research Parkway</s1><s2>Meriden, CT 06450</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Hemagglutinin</term><term>Influenza</term><term>Insecta</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Insecta</term><term>Hémagglutinine</term><term>Vaccin</term><term>Grippe</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple different hemagglutinin (HA) protein antigens have been reproducibly manufactured at the 650 L scale by Protein Sciences Corporation (PSC) based on an insect cell culture with baculovirus infection. Significantly, these HA protein antigens were produced by the same Universal Manufacturing process as described in the biological license application (BLA) for the first recombinant influenza vaccine approved by the FDA (Flublok®). The technology is uniquely designed so that a change in vaccine composition can be readily accommodated from one HA protein antigen to another one. Here we present a vaccine candidate to combat the recently emerged H7N9 virus as an example starting with the genetic sequence for the required HA, creation of the baculovirus and ending with purified protein antigen (or vaccine component) at the 10 L scale accomplished within 38 days under GMP conditions. The same process performance is being achieved at the 2L, 10L, 100 L, 650 L and 2500 L scale. An illustration is given of how the technology was transferred from the benchmark 650 L scale facility to a retrofitted microbial facility at the 2500 L scale within 100 days which includes the time for facility engineering changes. The successful development, technology transfer and scale-up of the Flublok® process has major implications for being ready to make vaccine rapidly on a worldwide scale as a defense against pandemic influenza. The technology described does not have the same vulnerability to mutations in the egg adapted strain, and resulting loss in vaccine efficacy, faced by egg based manufacture.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Connecticut</li><li>Grand Londres</li><li>Pennsylvanie</li></region><settlement><li>Londres</li></settlement><orgName><li>University College de Londres</li></orgName></list><tree><country name="États-Unis"><region name="Connecticut"><name sortKey="Buckland, Barry" sort="Buckland, Barry" uniqKey="Buckland B" first="Barry" last="Buckland">Barry Buckland</name></region><name sortKey="Boulanger, Robert" sort="Boulanger, Robert" uniqKey="Boulanger R" first="Robert" last="Boulanger">Robert Boulanger</name><name sortKey="Cox, Manon M J" sort="Cox, Manon M J" uniqKey="Cox M" first="Manon M. J." last="Cox">Manon M. J. Cox</name><name sortKey="Fino, Mireli" sort="Fino, Mireli" uniqKey="Fino M" first="Mireli" last="Fino">Mireli Fino</name><name sortKey="Holtz, Kathy" sort="Holtz, Kathy" uniqKey="Holtz K" first="Kathy" last="Holtz">Kathy Holtz</name><name sortKey="Khramtsov, Nikolai" sort="Khramtsov, Nikolai" uniqKey="Khramtsov N" first="Nikolai" last="Khramtsov">Nikolai Khramtsov</name><name sortKey="Kubera, Paul" sort="Kubera, Paul" uniqKey="Kubera P" first="Paul" last="Kubera">Paul Kubera</name><name sortKey="Mcpherson, Clifton" sort="Mcpherson, Clifton" uniqKey="Mcpherson C" first="Clifton" last="Mcpherson">Clifton Mcpherson</name><name sortKey="Meghrous, Jamal" sort="Meghrous, Jamal" uniqKey="Meghrous J" first="Jamal" last="Meghrous">Jamal Meghrous</name><name sortKey="Srivastava, Indresh" sort="Srivastava, Indresh" uniqKey="Srivastava I" first="Indresh" last="Srivastava">Indresh Srivastava</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Buckland, Barry" sort="Buckland, Barry" uniqKey="Buckland B" first="Barry" last="Buckland">Barry Buckland</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001008 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001008 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0246271
|texte= Technology transfer and scale-up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process
}}
| This area was generated with Dilib version V0.6.34. |  |